Chromadex Corp reports results for the quarter ended in December - Earnings Summary

Niagen Bioscience

06/03/2024 23:34

* Chromadex Corp  CDXC.OQ  reported quarterly breakeven
results​​
per share for the quarter ended in December, higher than the
same quarter last year, when the company reported EPS of -2
cents.  The mean expectation of four analysts for the quarter
was for a loss of 3 cents per share. Wall Street expected
results to range from -3 cents to -2 cents per share.
    * Revenue rose 1% to $21.20 million from a year ago;
analysts
expected $20.98 million. 
    * Chromadex Corp's reported EPS for the quarter was
breakeven
results​.
    * The company reported quarterly net income of $114
thousand.
    * Chromadex Corp shares had risen by 21.0% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Chromadex Corp is
$5.00 
This summary was machine generated from LSEG data March 6 at
11:34 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.03          0.00           Beat
 Sep. 30 2023      -0.03          -0.01          Beat
 Jun. 30 2023      -0.04          -0.03          Beat
 Mar. 31 2023      -0.05          -0.03          Beat